Monitoring treatment with cyclosporine microemulsion in myasthenia gravis

K. Utsugisawa, Y. Nagane, Shigeaki Suzuki, N. Suzuki

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: To examine whether the monitoring of cyclosporine (CsA) blood concentrations is of benefit in CsA microemulsion pre-concentrate (MEPC) therapy for myasthenia gravis (MG). Methods: We measured CsA blood concentrations both 2 h after administration (C2) and immediately before administration (C0) and examined associations with changes to clinical parameters in 20 MG patients treated with CsA MEPC in an unblinded, 6-month prospective open trial. Results: Initial dose of CsA MEPC (4.7 ± 0.5 mg/kg/day) provided both high C2 levels and safe C0 levels. Disease severity, daily dose of prednisolone, acetylcholine receptor-antibody titre levels and levels of interleukin-2 production by peripheral blood mononuclear cells were significantly reduced following treatment with CsA MEPC. A significant correlation existed between C2 levels following the initial dose and clinical improvement in responder MG patients. C0 levels were significantly higher in patients who exhibited increased serum creatinine or hypertension compared with patients free from side effects. Body mass index of individual patients was significantly correlated with C0 level, and may thus offer a useful marker to predict C0 levels. Discussion: CsA MEPC was effective at suppressing symptoms and T-cell-dependent pathogenesis of MG, and monitoring of C2 and C0 levels can be useful to estimate efficacy and safety of the drug.

Original languageEnglish
Pages (from-to)598-604
Number of pages7
JournalEuropean Journal of Neurology
Volume15
Issue number6
DOIs
Publication statusPublished - 2008 Jun

Fingerprint

Myasthenia Gravis
Cyclosporine
Therapeutics
Cholinergic Receptors
Interleukin-2
Blood Cells
Creatinine
Body Mass Index
Hypertension
T-Lymphocytes
Safety
Antibodies
Serum
Pharmaceutical Preparations

Keywords

  • C0
  • C2
  • Cyclosporine microemulsion pre-concentrate
  • Myasthenia gravis
  • Open trial

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Monitoring treatment with cyclosporine microemulsion in myasthenia gravis. / Utsugisawa, K.; Nagane, Y.; Suzuki, Shigeaki; Suzuki, N.

In: European Journal of Neurology, Vol. 15, No. 6, 06.2008, p. 598-604.

Research output: Contribution to journalArticle

Utsugisawa, K. ; Nagane, Y. ; Suzuki, Shigeaki ; Suzuki, N. / Monitoring treatment with cyclosporine microemulsion in myasthenia gravis. In: European Journal of Neurology. 2008 ; Vol. 15, No. 6. pp. 598-604.
@article{c3ff73d4e4734c33815d69f29578190e,
title = "Monitoring treatment with cyclosporine microemulsion in myasthenia gravis",
abstract = "Purpose: To examine whether the monitoring of cyclosporine (CsA) blood concentrations is of benefit in CsA microemulsion pre-concentrate (MEPC) therapy for myasthenia gravis (MG). Methods: We measured CsA blood concentrations both 2 h after administration (C2) and immediately before administration (C0) and examined associations with changes to clinical parameters in 20 MG patients treated with CsA MEPC in an unblinded, 6-month prospective open trial. Results: Initial dose of CsA MEPC (4.7 ± 0.5 mg/kg/day) provided both high C2 levels and safe C0 levels. Disease severity, daily dose of prednisolone, acetylcholine receptor-antibody titre levels and levels of interleukin-2 production by peripheral blood mononuclear cells were significantly reduced following treatment with CsA MEPC. A significant correlation existed between C2 levels following the initial dose and clinical improvement in responder MG patients. C0 levels were significantly higher in patients who exhibited increased serum creatinine or hypertension compared with patients free from side effects. Body mass index of individual patients was significantly correlated with C0 level, and may thus offer a useful marker to predict C0 levels. Discussion: CsA MEPC was effective at suppressing symptoms and T-cell-dependent pathogenesis of MG, and monitoring of C2 and C0 levels can be useful to estimate efficacy and safety of the drug.",
keywords = "C0, C2, Cyclosporine microemulsion pre-concentrate, Myasthenia gravis, Open trial",
author = "K. Utsugisawa and Y. Nagane and Shigeaki Suzuki and N. Suzuki",
year = "2008",
month = "6",
doi = "10.1111/j.1468-1331.2008.02130.x",
language = "English",
volume = "15",
pages = "598--604",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Monitoring treatment with cyclosporine microemulsion in myasthenia gravis

AU - Utsugisawa, K.

AU - Nagane, Y.

AU - Suzuki, Shigeaki

AU - Suzuki, N.

PY - 2008/6

Y1 - 2008/6

N2 - Purpose: To examine whether the monitoring of cyclosporine (CsA) blood concentrations is of benefit in CsA microemulsion pre-concentrate (MEPC) therapy for myasthenia gravis (MG). Methods: We measured CsA blood concentrations both 2 h after administration (C2) and immediately before administration (C0) and examined associations with changes to clinical parameters in 20 MG patients treated with CsA MEPC in an unblinded, 6-month prospective open trial. Results: Initial dose of CsA MEPC (4.7 ± 0.5 mg/kg/day) provided both high C2 levels and safe C0 levels. Disease severity, daily dose of prednisolone, acetylcholine receptor-antibody titre levels and levels of interleukin-2 production by peripheral blood mononuclear cells were significantly reduced following treatment with CsA MEPC. A significant correlation existed between C2 levels following the initial dose and clinical improvement in responder MG patients. C0 levels were significantly higher in patients who exhibited increased serum creatinine or hypertension compared with patients free from side effects. Body mass index of individual patients was significantly correlated with C0 level, and may thus offer a useful marker to predict C0 levels. Discussion: CsA MEPC was effective at suppressing symptoms and T-cell-dependent pathogenesis of MG, and monitoring of C2 and C0 levels can be useful to estimate efficacy and safety of the drug.

AB - Purpose: To examine whether the monitoring of cyclosporine (CsA) blood concentrations is of benefit in CsA microemulsion pre-concentrate (MEPC) therapy for myasthenia gravis (MG). Methods: We measured CsA blood concentrations both 2 h after administration (C2) and immediately before administration (C0) and examined associations with changes to clinical parameters in 20 MG patients treated with CsA MEPC in an unblinded, 6-month prospective open trial. Results: Initial dose of CsA MEPC (4.7 ± 0.5 mg/kg/day) provided both high C2 levels and safe C0 levels. Disease severity, daily dose of prednisolone, acetylcholine receptor-antibody titre levels and levels of interleukin-2 production by peripheral blood mononuclear cells were significantly reduced following treatment with CsA MEPC. A significant correlation existed between C2 levels following the initial dose and clinical improvement in responder MG patients. C0 levels were significantly higher in patients who exhibited increased serum creatinine or hypertension compared with patients free from side effects. Body mass index of individual patients was significantly correlated with C0 level, and may thus offer a useful marker to predict C0 levels. Discussion: CsA MEPC was effective at suppressing symptoms and T-cell-dependent pathogenesis of MG, and monitoring of C2 and C0 levels can be useful to estimate efficacy and safety of the drug.

KW - C0

KW - C2

KW - Cyclosporine microemulsion pre-concentrate

KW - Myasthenia gravis

KW - Open trial

UR - http://www.scopus.com/inward/record.url?scp=43549098291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549098291&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2008.02130.x

DO - 10.1111/j.1468-1331.2008.02130.x

M3 - Article

C2 - 18410372

AN - SCOPUS:43549098291

VL - 15

SP - 598

EP - 604

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 6

ER -